Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025

Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice.

View Full Paper
Ask AI
Bookmark
Share

Authors

PVProkop VodičkaIHIva HamováAVAdriana Velasova

Discussion

Loading...

Member takes

Overview

Assessment of circulating tumour DNA predicts treatment outcomes in diffuse large B-cell lymphoma, suggesting improved risk stratification.

Key Points

  • Baseline circulating tumour DNA level is an independent predictor of treatment outcome, enhancing patient management.
  • Achievement of minimal residual disease negativity correlates with better treatment outcomes in diffuse large B-cell lymphoma.
  • Interim minimal residual disease positivity alongside imaging findings indicates a high-risk subgroup of patients.
  • Using a targeted sequencing approach enhances the ability to assess circulating tumour DNA levels effectively.

Cite This Study

Vodička et al. (2025) studied this question.

synapsesocial.com/papers/68c199e89b7b07f3a061b617https://doi.org/10.1111/bjh.70128
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma2024 · 11 citations
  2. 2Liquid biopsy for molecular characterization of diffuse large B‐cell lymphoma and early assessment of minimal residual disease2024 · 27 citations
  3. 3Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?2024 · 11 citations
  4. 4DLBCL: who is high risk and how should treatment be optimized?2023 · 30 citations
  5. 5Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma2018 · 509 citations